Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.6K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

425
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
425
Nursing Clinical Information System01:27

Nursing Clinical Information System

1.3K
Nursing Clinical Information System (NCIS)
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
1.3K
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

3.7K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prion-like transmission and propagation of human β-amyloid to the bank vole rodent model.

Acta neuropathologica·2026
Same author

Prevalence of Lewy body pathology and phenotypic associations in patients with mild cognitive impairment: Evidence from the Interceptor study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Mild cognitive impairment-to-Alzheimer's dementia progression risk: the contribution of the Interceptor project.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

D178N prion protein mutation endows RML prions with new strain properties that do not mimic human genetic prion diseases.

Acta neuropathologica·2026
Same author

Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism.

Brain sciences·2026
Same author

Plasma extracellular vesicles and phosphorylated tau 181 as early biomarkers of cognitive impairment in Alzheimer's dementia.

Alzheimer's research & therapy·2026
Same journal

Preface.

Handbook of clinical neurology·2026
Same journal

Foreword.

Handbook of clinical neurology·2026
Same journal

Fundus autofluorescence imaging.

Handbook of clinical neurology·2026
Same journal

The electroretinogram as a means to study the physiology of the retina.

Handbook of clinical neurology·2026
Same journal

Adaptive optics scanning light ophthalmoscopy.

Handbook of clinical neurology·2026
Same journal

Modeling the human retina in a dish: Advances and future directions.

Handbook of clinical neurology·2026
See all related articles

Related Experiment Video

Updated: Feb 9, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

Clinical trials.

Simon Mead1, Fabrizio Tagliavini2

  • 1National Prion Clinic, National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, and MRC Prion Unit at University College London Institute of Prion Diseases, London, United Kingdom.

Handbook of Clinical Neurology
|June 12, 2018
PubMed
Summary
This summary is machine-generated.

Developing effective treatments for human prion diseases requires optimized clinical trial designs. Future trials will incorporate novel outcome measures and biomarkers for improved success rates in Creutzfeldt-Jakob disease research.

Keywords:
CJDCreutzfeldt-Jakobbiomarkerclinical trialprion

More Related Videos

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K

Related Experiment Videos

Last Updated: Feb 9, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K
Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
14:45

Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay

Published on: September 16, 2012

15.5K

Area of Science:

  • Neuroscience
  • Clinical Research
  • Drug Development

Background:

  • Human prion diseases, such as Creutzfeldt-Jakob disease, lack effective treatments.
  • Clinical trials are essential for treatment development but face challenges due to disease rarity and rapid progression.
  • Past trials have primarily used repurposed drugs and survival as endpoints, with limitations.

Purpose of the Study:

  • To review the challenges and advancements in clinical trial design for human prion diseases.
  • To explore potential improvements in outcome measures and patient populations for future studies.
  • To guide the development of targeted therapies for prion diseases.

Main Methods:

  • Review of existing clinical trial methodologies for prion diseases.
  • Analysis of limitations in current trial endpoints and outcome measures.
  • Discussion of emerging biomarkers and alternative patient populations for future trials.

Main Results:

  • Traditional gold-standard trial designs are difficult to implement for Creutzfeldt-Jakob disease.
  • Repurposed drugs like doxycycline, quinacrine, pentosan polysulfate (PPS), and flupertine have been tested.
  • Survival is a common but limited endpoint; biomarkers show potential as secondary outcomes.
  • New outcome measures and biomarkers for neuronal damage or prion seeding activity may enhance trial sensitivity.

Conclusions:

  • Optimizing clinical trial design is critical for discovering effective prion disease treatments.
  • Future research should consider novel outcome measures, sensitive biomarkers, and at-risk populations.
  • Development of specifically designed anti-prion compounds will be key for future therapeutic advancements.